Xinjiang Baihuacun Co Ltd (600721) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xinjiang Baihuacun Co Ltd (600721) has a cash flow conversion efficiency ratio of 0.022x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥17.27 Million ≈ $2.53 Million USD) by net assets (CN¥793.82 Million ≈ $116.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 600721 stock market capitalisation for the company's overall valuation and market capitalisation.
Xinjiang Baihuacun Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Xinjiang Baihuacun Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Xinjiang Baihuacun Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xinjiang Baihuacun Co Ltd ranked by their cash flow conversion efficiency. Explore 600721 cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Phibro Animal Health Corporation
NASDAQ:PAHC
|
0.063x |
|
Wave Life Sciences Ltd
NASDAQ:WVE
|
-0.116x |
|
PWR Holdings Ltd
AU:PWH
|
0.100x |
|
WAVE LIFE SCIENCES LTD.
F:1U5
|
-0.116x |
|
Harim Holdings Co. Ltd
KQ:003380
|
0.055x |
|
Bear Electric Appliance Co Ltd
SHE:002959
|
-0.001x |
|
Fidus Investment Corp
NASDAQ:FDUS
|
0.018x |
|
Esperion Therapeutics Inc
NASDAQ:ESPR
|
0.009x |
Annual Cash Flow Conversion Efficiency for Xinjiang Baihuacun Co Ltd (1998–2025)
The table below shows the annual cash flow conversion efficiency of Xinjiang Baihuacun Co Ltd from 1998 to 2025. View 600721 stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥803.14 Million ≈ $117.52 Million |
CN¥32.94 Million ≈ $4.82 Million |
0.041x | -61.24% |
| 2024-12-31 | CN¥758.58 Million ≈ $111.00 Million |
CN¥80.29 Million ≈ $11.75 Million |
0.106x | +20.47% |
| 2023-12-31 | CN¥706.62 Million ≈ $103.40 Million |
CN¥62.08 Million ≈ $9.08 Million |
0.088x | +10.20% |
| 2022-12-31 | CN¥667.02 Million ≈ $97.61 Million |
CN¥53.18 Million ≈ $7.78 Million |
0.080x | +57.57% |
| 2021-12-31 | CN¥686.25 Million ≈ $100.42 Million |
CN¥34.72 Million ≈ $5.08 Million |
0.051x | +235.65% |
| 2020-12-31 | CN¥624.16 Million ≈ $91.33 Million |
CN¥-23.28 Million ≈ $-3.41 Million |
-0.037x | -424.03% |
| 2019-12-31 | CN¥954.70 Million ≈ $139.70 Million |
CN¥-6.80 Million ≈ $-994.38K |
-0.007x | -108.13% |
| 2018-12-31 | CN¥919.58 Million ≈ $134.56 Million |
CN¥80.55 Million ≈ $11.79 Million |
0.088x | +402.05% |
| 2017-12-31 | CN¥1.73 Billion ≈ $253.60 Million |
CN¥-50.26 Million ≈ $-7.35 Million |
-0.029x | +38.46% |
| 2016-12-31 | CN¥2.30 Billion ≈ $336.33 Million |
CN¥-108.32 Million ≈ $-15.85 Million |
-0.047x | -105.06% |
| 2015-12-31 | CN¥455.10 Million ≈ $66.60 Million |
CN¥423.58 Million ≈ $61.98 Million |
0.931x | +359.15% |
| 2014-12-31 | CN¥997.28 Million ≈ $145.93 Million |
CN¥202.16 Million ≈ $29.58 Million |
0.203x | +4033.04% |
| 2013-12-31 | CN¥1.35 Billion ≈ $197.86 Million |
CN¥6.63 Million ≈ $970.41K |
0.005x | -98.42% |
| 2012-12-31 | CN¥1.10 Billion ≈ $161.59 Million |
CN¥342.00 Million ≈ $50.05 Million |
0.310x | -39.25% |
| 2011-12-31 | CN¥1.10 Billion ≈ $160.64 Million |
CN¥559.64 Million ≈ $81.89 Million |
0.510x | +57.70% |
| 2010-12-31 | CN¥1.05 Billion ≈ $153.51 Million |
CN¥339.11 Million ≈ $49.62 Million |
0.323x | +3376.14% |
| 2009-12-31 | CN¥361.61 Million ≈ $52.92 Million |
CN¥-3.57 Million ≈ $-522.12K |
-0.010x | -127.73% |
| 2008-12-31 | CN¥344.28 Million ≈ $50.38 Million |
CN¥12.25 Million ≈ $1.79 Million |
0.036x | +8.30% |
| 2007-12-31 | CN¥337.41 Million ≈ $49.37 Million |
CN¥11.09 Million ≈ $1.62 Million |
0.033x | -90.13% |
| 2006-12-31 | CN¥19.48 Million ≈ $2.85 Million |
CN¥6.48 Million ≈ $948.37K |
0.333x | -89.36% |
| 2005-12-31 | CN¥2.59 Million ≈ $378.62K |
CN¥8.10 Million ≈ $1.18 Million |
3.129x | +615.11% |
| 2004-12-31 | CN¥218.65 Million ≈ $32.00 Million |
CN¥95.66 Million ≈ $14.00 Million |
0.438x | +249.96% |
| 2003-12-31 | CN¥229.91 Million ≈ $33.64 Million |
CN¥-67.07 Million ≈ $-9.81 Million |
-0.292x | -55.16% |
| 2002-12-31 | CN¥178.77 Million ≈ $26.16 Million |
CN¥-33.61 Million ≈ $-4.92 Million |
-0.188x | -170.68% |
| 2001-12-31 | CN¥122.68 Million ≈ $17.95 Million |
CN¥32.63 Million ≈ $4.78 Million |
0.266x | +1147.30% |
| 2000-12-31 | CN¥130.41 Million ≈ $19.08 Million |
CN¥-3.31 Million ≈ $-484.70K |
-0.025x | -1168.25% |
| 1999-12-31 | CN¥221.52 Million ≈ $32.41 Million |
CN¥-443.64K ≈ $-64.92K |
-0.002x | +98.47% |
| 1998-12-31 | CN¥273.24 Million ≈ $39.98 Million |
CN¥-35.82 Million ≈ $-5.24 Million |
-0.131x | -- |
About Xinjiang Baihuacun Co Ltd
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd engages in pharmaceutical research and development, clinical trials, biomedicine, commercial properties, and other businesses. It also offers comprehensive contract research organization (CRO) solutions, including one-stop, full-process services for drug R&D, such as Phase I to IV clinical trials, bioequivalence and pharmacokinetics testing, medical scienc… Read more